Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Phylogica Taps Isogenica’s In Vitro Display Technology

  • Australian-based biopharmaceutical company Phylogica will use Isogenica’s CIS display technology to optimize the performance of three of its lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

    CIS display, an in vitro display technology, allows the generation of polypeptide libraries of unprecedented size and complexity, according to Isogenica. It is then possible to select polypeptides with high affinity and specificity for most targets, the company continues.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »